Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Rising Government Initiatives
3.2.2. Incidence Of Cancer Cases In Older Populace
3.2.3. Shifting Demand Of Consumers For Diagnostic Centers
3.2.4. Non-Invasive Nature Of Liquid Biopsy Testing
3.2.5. Emergence Of Tissue/Tumor-Agnostic Drugs
3.2.6. Patients’ Preference For Liquid Biopsy Testing
3.2.7. Technological Advancements
3.3. Key Restraints
3.3.1. Lack Of Consensus On Standard Operating Procedures (Sops)
3.3.2. Poor Compensation Structures
3.3.3. High Cost Of The Test
3.3.4. Reimbursement Issues
3.3.5. Dearth Of Skilled Professionals

4. Key Analytics
4.1. Porter’S Five Forces Analysis
4.1.1. Threat Of New Entries
4.1.2. Threat Of Substitutions
4.1.3. Buyers Power
4.1.4. Suppliers Power
4.1.5. Competitive Rivalry
4.2. Impact Of Covid-19 On Liquid Biopsy Market
4.3. Key Liquid Biopsy Initiatives
4.4. Regulatory Framework
4.5. Opportunity Matrix
4.6. Vendor Landscape
4.7. Key Investment Insights

5. Market By Therapeutic Application
5.1. Lung Cancer
5.2. Breast Cancer
5.3. Prostate Cancer
5.4. Colorectal Cancer
5.5. Melanoma Cancer
5.6. Other Types Of Cancer
5.7. Non-Oncology Application

6. Market By Clinical Application
6.1. Treatment Monitoring
6.2. Prognosis And Reoccurrence Monitoring
6.3. Treatment Selection
6.4. Diagnosis And Screening

7. Market By Biomarker Type
7.1. Nucleic Acid
7.2. Protein
7.3. Extracellular Vesicles
7.4. Cells

8. Market By Analysis Platform
8.1. Ngs
8.2. Microarray
8.3. Pcr
8.4. Proteomics
8.5. Other Analysis Platforms

9. Market By Analysis Purpose
9.1. Early Detection/Screening
9.2. Therapy Guidance
9.3. Monitoring
9.4. Diagnosis

10. Market By Product
10.1. Circulating Tumor Dna (Ctdna)
10.2. Circulating Tumor Cells (Ctcs)
10.3. Cell-Free Dna (Cfdna)
10.4. Extracellular Vesicles And Others

11. Market By End-User
11.1. Physicians’ Office Laboratories
11.2. Hospitals
11.3. Clinical Diagnostic Laboratories

12. Geographical Analysis
12.1. North America
12.1.1. Market Size & Estimates
12.1.2. Key Growth Enablers
12.1.3. Key Challenges
12.1.4. Key Players
12.1.5. Country Analysis
12.1.5.1. United States
12.1.5.2. Canada
12.2. Europe
12.2.1. Market Size & Estimates
12.2.2. Key Growth Enablers
12.2.3. Key Challenges
12.2.4. Key Players
12.2.5. Country Analysis
12.2.5.1. United Kingdom
12.2.5.2. France
12.2.5.3. Germany
12.2.5.4. Italy
12.2.5.5. Russia
12.2.5.6. Belgium
12.2.5.7. Poland
12.2.5.8. Rest Of Europe
12.3. Asia-Pacific
12.3.1. Market Size & Estimates
12.3.2. Key Growth Enablers
12.3.3. Key Challenges
12.3.4. Key Players
12.3.5. Country Analysis
12.3.5.1. Japan
12.3.5.2. China
12.3.5.3. India
12.3.5.4. South Korea
12.3.5.5. Australia & New Zealand
12.3.5.6. Thailand
12.3.5.7. Indonesia
12.3.5.8. Vietnam
12.3.5.9. Rest Of Asia-Pacific
12.4. Rest Of World
12.4.1. Market Size & Estimates
12.4.2. Key Growth Enablers
12.4.3. Key Challenges
12.4.4. Key Players
12.4.5. Regional Analysis
12.4.5.1. Latin America
12.4.5.2. Middle East & Africa

13. Competitive Landscape
13.1. Key Strategic Developments
13.1.1. Mergers & Acquisitions
13.1.2. Product Launches & Developments
13.1.3. Partnerships, Contracts/Agreements & Collaborations
13.1.4. Business Expansions/ Approvals/ Announcements
13.2. Company Profiles
13.2.1. Adaptive Biotechnologies
13.2.2. Agilent Technologies Inc
13.2.3. Angle Plc
13.2.4. Becton, Dickinson And Company (Bd)
13.2.5. Biocept Inc
13.2.6. Bio-Rad Laboratories Inc
13.2.7. F. Hoffmann-La Roche
13.2.8. Foundation Medicine
13.2.9. Grail
13.2.10. Guardant Health Inc
13.2.11. Illumina Inc
13.2.12. Mdxhealth Sa
13.2.13. Menarini-Silicon Biosystems
13.2.14. Myriad Genetics Inc
13.2.15. Natera
13.2.16. Personal Genome Diagnostics
13.2.17. Qiagen Nv
13.2.18. Thermo Fisher Scientific Inc



List of Figures


Figure 1: Porter’S Five Forces Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: Global Liquid Biopsy Market, By Therapeutic Application, In 2020
Figure 6: Global Liquid Biopsy Market, By Lung Cancer, 2021-2028 (In $ Million)
Figure 7: Global Liquid Biopsy Market, By Breast Cancer, 2021-2028 (In $ Million)
Figure 8: Global Liquid Biopsy Market, By Prostate Cancer, 2021-2028 (In $ Million)
Figure 9: Global Liquid Biopsy Market, By Colorectal Cancer, 2021-2028 (In $ Million)
Figure 10: Global Liquid Biopsy Market, By Melanoma Cancer, 2021-2028 (In $ Million)
Figure 11: Global Liquid Biopsy Market, By Other Types Of Cancer, 2021-2028 (In $ Million)
Figure 12: Global Liquid Biopsy Market, By Non-Oncology Application, 2021-2028 (In $ Million)
Figure 13: Global Liquid Biopsy Market, By Clinical Application, In 2020
Figure 14: Global Liquid Biopsy Market, By Treatment Monitoring, 2021-2028 (In $ Million)
Figure 15: Global Liquid Biopsy Market, By Prognosis And Reoccurrence Monitoring, 2021-2028 (In $ Million)
Figure 16: Global Liquid Biopsy Market, By Treatment Selection, 2021-2028 (In $ Million)
Figure 17: Global Liquid Biopsy Market, By Diagnosis And Screening, 2021-2028 (In $ Million)
Figure 18: Global Liquid Biopsy Market, By Biomarker Type, In 2020
Figure 19: Global Liquid Biopsy Market, By Nucleic Acid, 2021-2028 (In $ Million)
Figure 20: Global Liquid Biopsy Market, By Protein, 2021-2028 (In $ Million)
Figure 21: Global Liquid Biopsy Market, By Extracellular Vesicles, 2021-2028 (In $ Million)
Figure 22: Global Liquid Biopsy Market, By Cells, 2021-2028 (In $ Million)
Figure 23: Global Liquid Biopsy Market, By Analysis Platform, In 2020
Figure 24: Global Liquid Biopsy Market, By Ngs, 2021-2028 (In $ Million)
Figure 25: Global Liquid Biopsy Market, By Microarray, 2021-2028 (In $ Million)
Figure 26: Global Liquid Biopsy Market, By Pcr, 2021-2028 (In $ Million)
Figure 27: Global Liquid Biopsy Market, By Proteomics, 2021-2028 (In $ Million)
Figure 28: Global Liquid Biopsy Market, By Other Analysis Platforms, 2021-2028 (In $ Million)
Figure 29: Global Liquid Biopsy Market, By Analysis Purpose, In 2020
Figure 30: Global Liquid Biopsy Market, By Early Detection/Screening, 2021-2028 (In $ Million)
Figure 31: Global Liquid Biopsy Market, By Therapy Guidance, 2021-2028 (In $ Million)
Figure 32: Global Liquid Biopsy Market, By Monitoring, 2021-2028 (In $ Million)
Figure 33: Global Liquid Biopsy Market, By Diagnosis, 2021-2028 (In $ Million)
Figure 34: Global Liquid Biopsy Market, By Product, In 2020
Figure 35: Global Liquid Biopsy Market, By Circulating Tumor Dna (Ctdna), 2021-2028 (In $ Million)
Figure 36: Global Liquid Biopsy Market, By Circulating Tumor Cells (Ctcs), 2021-2028 (In $ Million)
Figure 37: Global Liquid Biopsy Market, By Cell-Free Dna (Cfdna), 2021-2028 (In $ Million)
Figure 38: Global Liquid Biopsy Market, By Extracellular Vesicles And Others, 2021-2028 (In $ Million)
Figure 39: Global Liquid Biopsy Market, By End-User, In 2020
Figure 40: Global Liquid Biopsy Market, By Physicians’ Office Laboratories, 2021-2028 (In $ Million)
Figure 41: Global Liquid Biopsy Market, By Hospitals, 2021-2028 (In $ Million)
Figure 42: Global Liquid Biopsy Market, By Clinical Diagnostic Laboratories, 2021-2028 (In $ Million)
Figure 43: North America Liquid Biopsy Market, Country Outlook, 2020 & 2028 (In %)
Figure 44: United States Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 45: Canada Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 46: Europe Liquid Biopsy Market, Country Outlook, 2020 & 2028 (In %)
Figure 47: United Kingdom Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 48: France Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 49: Germany Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 50: Italy Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 51: Russia Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 52: Belgium Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 53: Poland Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 54: Rest Of Europe Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 55: Asia-Pacific Liquid Biopsy Market, Country Outlook, 2020 & 2028 (In %)
Figure 56: Japan Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 57: China Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 58: India Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 59: South Korea Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 60: Australia & New Zealand Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 61: Thailand Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 62: Indonesia Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 63: Vietnam Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 64: Rest Of Asia-Pacific Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 65: Rest Of World Liquid Biopsy Market, Regional Outlook, 2020 & 2028 (In %)
Figure 66: Latin America Liquid Biopsy Market, 2021-2028 (In $ Million)
Figure 67: Middle East & Africa Liquid Biopsy Market, 2021-2028 (In $ Million)


List of Tables


TABLE 1: MARKET SNAPSHOT - LIQUID BIOPSY
TABLE 2: GOVERNMENT INITIATIVES FOR CANCER AND LIQUID BIOPSY TESTING IN SOME COUNTRIES
TABLE 3: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 4: GLOBAL LIQUID BIOPSY MARKET, BY THERAPEUTIC APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 5: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 6: GLOBAL LIQUID BIOPSY MARKET, BY CLINICAL APPLICATION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 7: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 8: GLOBAL LIQUID BIOPSY MARKET, BY BIOMARKER TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 9: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 10: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PLATFORM, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 11: NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES
TABLE 12: ADVANTAGES OF DROPLET DIGITAL PCR FOR SINGLE-CELL ANALYSIS
TABLE 13: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 14: GLOBAL LIQUID BIOPSY MARKET, BY ANALYSIS PURPOSE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 15: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 16: GLOBAL LIQUID BIOPSY MARKET, BY PRODUCT, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 17: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 18: GLOBAL LIQUID BIOPSY MARKET, BY END-USER, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 19: GLOBAL LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 20: GLOBAL LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 21: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 22: NORTH AMERICA LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 23: LEADING PLAYERS OPERATING IN NORTH AMERICA LIQUID BIOPSY MARKET
TABLE 24: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 25: EUROPE LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 26: LEADING PLAYERS OPERATING IN EUROPE LIQUID BIOPSY MARKET
TABLE 27: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 28: ASIA-PACIFIC LIQUID BIOPSY MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 29: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
TABLE 30: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 31: REST OF WORLD LIQUID BIOPSY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 32: LEADING PLAYERS OPERATING IN ASIA-PACIFIC LIQUID BIOPSY MARKET
TABLE 33: LIST OF MERGERS & ACQUISITIONS
TABLE 34: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 35: LIST OF PARTNERSHIPS AND AGREEMENTS
TABLE 36: LIST OF BUSINESS EXPANSIONS AND DIVESTITURES